openPR Logo
Press release

Rivaroxaban Market 2018 Revenue And Key Players | Janssen Pharmaceuticals Inc. and Bayer AG

03-20-2019 02:18 PM CET | Arts & Culture

Press release from: Coherent Market Insights

Rivaroxaban

Rivaroxaban

Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc.

Xarelto is among the most popular anticoagulants, which includes brands like Caumadin, Praxada, and Eliquis. The trajectory growth of rivaroxaban market can be attributed to increasing clinical trials by companies and universities to expand the indication of the drug or to use in combination with other drug.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/1962

For instance, the University Hospital Inselspital, Berne, in collaboration with Bayer and Janssen, and two others, are studying the efficacy of rivaroxaban in patients undergoing bariatric surgery and as on May 2018, the trial was under phase II.

Market players strategize to strengthen their foot hold in the market in spite of high cost by implementing cost-effective treatment schemes. For instance, Janssen Pharmaceuticals offer Xarelto manufacturer coupon or patient assistance program to lower the cost of the drug.

The market players of rivaroxaban market are also concentrating on enhancing effectiveness and reducing the side effects such as bleeding of the drug. For instance, as of June 2018, Janssen Scientific Affairs, LLC is studying the effectiveness of Xarelto with a mobile adherence platform, to improve medication adherence in patients with atrial fibrillation.

However, the presence of cheaper alternative drugs such as warfarin, apixaban, and dabigatran are expected to be major factors hindering the rivaroxaban market growth. The treatment cost using warfarin is as low as US$ 4 per month whereas the cost of rivaroxaban is around US$ 450 per month. This vast difference in cost of the drug lead the patients towards adopting cheaper alternative, thereby negatively affecting the market growth.

Get Request Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/1962

Detailed Segmentation:

Global Rivaroxaban Market, By Strength:
10 mg
15 mg
20 mg
Global Rivaroxaban Market, By Application:
Deep Vein Thrombosis Prophylaxis
Pulmonary Embolism
Global Rivaroxaban Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rivaroxaban Market 2018 Revenue And Key Players | Janssen Pharmaceuticals Inc. and Bayer AG here

News-ID: 1664967 • Views: 438

More Releases from Coherent Market Insights

Global Automotive Driving Simulator Market Expansion to be Persistent During 201 …
In this Report Titled Global Automotive Driving Simulator Market Growth (Status and Outlook) 2019-2026 the latest data has been delivered, along with collection of realistic information, quantitative and qualitative estimation by industry experts, and the contribution from industry associates across the value chain. This report is a vast research database spread across various pages with numerous tables, charts, and figures in it. This report presents a close watch on the
Airport Automated Security Screening Market by 2026 Capacity, Production, Revenu …
In this Report Titled Global Airport Automated Security Screening Market Growth (Status and Outlook) 2019-2026 the latest data has been delivered, along with collection of realistic information, quantitative and qualitative estimation by industry experts, and the contribution from industry associates across the value chain. This report is a vast research database spread across various pages with numerous tables, charts, and figures in it. This report presents a close watch on
Important Facts about Desktop-as-a-Service Market You Should Know
Desktop-as-a-service is a virtual workspace that helps to bring desktop, applications, data, and IT services in a single cloud-based solution. In a competitive market, companies have to overcome multiple challenges such as budgets, security, making data and applications available on multiple platforms, and remote access computing. To overcome these issues, organizations adopt to Desktop-as-a-service (DaaS), which is a desktop virtualization approach, to upgrade organization from a physical to virtual desktop
ENT Disorder Treatment Market 2020 - 2026 | Future Opportunities By Top Players …
Global ENT Disorder Treatment Market Report that covers exclusive and analytical data through the span of seven years between 2020-2026. This report is exclusive and encompasses in-depth analysis and industry insights on Global ENT Disorder Treatment Market. What you will get by reading the report is not just charts, bars, analytical data but also a better understanding of the market which will in turn help you make decisions in the

All 5 Releases


More Releases for Rivaroxaban

Rivaroxaban Market Industry Landscape And Acknowledgement with Top Players Janss …
The global rivaroxaban market size is estimated to be valued at US$ 5,653 million in 2017 and is expected to witness a CAGR of 1.5% over the forecast period (2018 – 2026) on account of patent expiry during the forecast period. Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and
Rivaroxaban Market Insights – Stop the Clot
Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC. Xarelto is approved for indications such as stroke prevention in non-valvular atrial fibrillation, pulmonary embolism, deep vein
Rivaroxaban
Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc. Xarelto is
Rivaroxaban Market - Global Outlook 2026 By TWO KEY Players Janssen Pharmaceutic …
Rivaroxaban is an oral anticoagulant, which was developed by Bayer and sold under the brand name Xarelto. The drug is indicated for the treatment of deep vein thrombosis prophylaxis or pulmonary embolism and to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). The drug is marketed by Bayer outside the U.S. and in the U.S., it is marketed by Janssen Pharmaceuticals, Inc. Xarelto is
Rivaroxaban Market to Gain US$ 7890 million by 2022 | Global Key Players – Bay …
A fresh report has been added to the wide database of Business Industry Reports. The research study is titled “Rivaroxaban Market” by Manufacturers, Countries, Type and Application, Forecast to 2022 which provides important data about the production, consumption, revenue and company profiles for key industry participants. Global Rivaroxaban Market Synopsis: According to Market Analyst, Global Rivaroxaban Market is projected to grow at a healthy growth rate from 2019 to 2022. Get Exclusive Sample
Global Rivaroxaban Market to Surpass US$ 7.0 Billion by 2026: CMI
The Global Rivaroxaban Market, by Strength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 5,653 million in 2017 and is projected to exhibit a CAGR of 1.5% over the forecast period